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CONTEXT AND OBJECTIVE: Studies using radio-
nuclides are the most appropriate method for 
estimating renal function. Dimercaptosuccinic 
acid chelate labeled with technetium-99m (99mTc-
DMSA) is the radiopharmaceutical of choice for 
high-resolution imaging of the renal cortex and 
estimation of the functional renal mass. The aim 
of this study was to evaluate a simplifi ed method 
for determining the absolute renal uptake (ARU) 
of 99mTc-DMSA prior to nephrectomy, using the 
radioactivity counts of nephrectomy specimens 
as the gold standard.
DESIGN AND SETTING: Prospective study at the 
Division of Nuclear Medicine, Department of Ra-
diology, Universidade Estadual de Campinas.
METHODS: Seventeen patients (12 females; 
range 22-82 years old; mean age 50.8 years 
old) underwent nephrectomy for various reasons. 
Renal scintigraphy was performed three to four 
hours after intravenous administration of a mean 
dose of 188.7 MBq (5.1 mCi) of 99mTc-DMSA, 
which was done six to 24 hours before surgery. 
The in vivo renal uptake of 99mTc-DMSA was 
determined using the radioactivity of the syringe 
before the injection (measured using a dose 
calibrator) and the images of the syringe and 
kidneys, obtained from a scintillation camera. 
After surgery, the reference value for renal uptake 
of 99mTc-DMSA was determined by measuring the 
radioactivity of the nephrectomy specimen using 
the same dose calibrator.
RESULTS: The ARU measurements were very 
similar to those obtained using the reference 
method, as determined by linear regression 
(r-squared = 0.96).
CONCLUSION: ARU estimation using the pro-
posed method before nephrectomy seems to be 
accurate and feasible for routine use.
KEY WORDS: 99mTc-DMSA. Scintigraphy. Ne-
phrectomy. Kidney cortex. Nuclear medicine.
INTRODUCTION
Studies using radionuclides are the most 
appropriate method for estimating renal 
function, to add functional information 
to anatomical studies such as ultrasound 
and X-ray methods. Dimercaptosuccinic 
acid chelate labeled with technetium-99m 
(99mTc-DMSA) was introduced in the early 
1970s1,2 and, ever since, it has been the radio-
pharmaceutical of choice for high-resolution 
imaging of the renal cortex and estimation of 
the functional renal mass.3
Several studies have demonstrated excel-
lent correlation between 99mTc-DMSA uptake 
and creatinine clearance,4 para-aminohippuric 
acid (PAH) clearance5 and renal technetium-
99m diethylenetriamine pentaacetic acid 
(99mTc-DTPA) accumulation.6,7
Different techniques to measure the ab-
solute uptake of 99mTc-DMSA by the kidneys 
have been described using planar scintigraphy 
and single photon emission computed tomog-
raphy (SPECT), but the methods remain too 
complex for routine use.8,9 Moreover, none 
of these techniques for in vivo quantifi ca-
tion of isolated renal 99mTc-DMSA uptake has 
been compared with ex vivo determination of 
renal uptake.
OBJECTIVE
The aim of this study was to evaluate a 
simplifi ed method for determining the abso-
lute renal uptake (ARU) of 99mTc-DMSA, 
using the radioactive counts from nephrec-
tomy specimens as the reference. 
METHODS
Type of study
This was a prospective study conducted 
in a tertiary public institution.
Patients
Seventeen patients were studied: twelve 
females and fi ve males, ranging from 22 to 
82 years of age (mean 50.8 years). All of these 
patients had been selected for nephrectomy by 
means of open or laparoscopic surgery, because 
of chronic pyelonephritis (eleven patients) or 
neoplasia (six patients) (Table 1). All patients 
signed a consent form that had been approved 
by the Institution’s Ethics Committee.
The weight (in kg) and height (in cm) of 
all patients were measured for subsequent use 
in the Tonnensen equations for kidney depth 
estimation10 (see image processing).
Radiopharmaceutical 
preparation
The radiopharmaceutical was reconsti-
tuted in accordance with the manufacturer’s 
instructions (CIS Bio International DMSA 
agent, Gif-sur-Yvette, France; IPEN Mo-
lybdenum generator [Mo-99-Tc99m], São 
Paulo, Brazil).
The labeling effi ciency was determined 
by means of thin layer chromatography silica 
gel (TLC-SG) kits (Merck, Darmstadt, Ger-
many). The syringes with the doses of 99mTc-
DMSA were measured in a dose calibrator 
(Capintec CRC-15R, Ramsey, New Jersey, 
United States). The doses ranged from 173.9 
to 207.2 MBq (4.7 to 5.6 mCi), with a mean 
dose of 188.7 MBq (5.1 mCi). After intrave-
nous injection, the residual radioactivity of the 
syringes was also measured. The radioactivity 
administered to the patients was calculated by 
subtracting this residual radioactivity from the 
syringe radioactivity before injection.
Syringe images
The syringes containing the 99mTc-DMSA 
dose were imaged before intravenous adminis-
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tration to the patients, to determine the effi-
ciency of the scintillation camera detector. The 
images were acquired for 120 seconds (matrix 
256 x 256, zoom 1.8) in a single-head scintil-
lation camera equipped with a high-resolution 
collimator (SP4 HR Elscint-General Electric, 
Haifa, Israel).
To keep the radioactivity measured in the 
syringes within the linear range of the detector, 
the syringes were placed inside a lead cylinder 
during acquisition. This lead cylinder was 
developed by the Institution’s Physics Division 
and consisted of a cylindrical polyvinyl chloride 
(PVC) tube of 3.8 cm in diameter by 20.3 cm 
in length inside a lead sheath of 0.1 cm in 
thickness. The attenuation correction factor was 
obtained experimentally, as follows.
Determination of the lead 
device attenuation correction 
factor
Radioactivity counts were acquired ten 
times for each of five samples of techne-
tium-99m with different radioactivity levels 
(18.5 MBq; 37 MBq; 74 MBq; 148 MBq; 
222 MBq) with the syringes inside the lead cyl-
inder, using the same scintillation camera and 
acquisition parameters. All acquisitions were 
then repeated without the lead cylinder.
After decay and background corrections, 
the mean count for each technetium-99m 
sample was determined. The data obtained 
with and without the lead device were plotted 
on two graphs and the attenuation correction 
factor for the cylinder was then obtained by 
dividing the two angular coefficients, resulting 
in the factor 2.8087.
Patient images
Renal scintigraphy was performed three to 
four hours after administering the radiophar-
maceutical, and six to 24 hours prior to surgery. 
Posterior view images in the supine position 
(matrix 256 x 256; zoom 1.8) were acquired 
with 800,000 counts, using the same camera 
as used for syringe imaging (Figure 1A). Tracer 
extravasation to soft tissue during injection did 
not occur in any of the patients, as demonstrated 
by imaging each patient’s injection site.
The same couch and position used 
to acquire the patient images were also used to 
acquire the syringe image, in order to stan-
dardize the attenuation factor.
Image processing
Determination of renal counts per 
second
Using the isocontour method (30%), 
regions of interest (ROIs) were drawn over 
Table 1. Characteristics of the patients who underwent nephrectomy
Patient Gender Age Histopathology
1 Female 56 Chronic pyelonephritis
2 Female 66 Chronic pyelonephritis
3 Female 28 Renal angiomyolipoma
4 Male 82 Urothelial carcinoma of the kidney pelvis and atrophy of the renal parenchyma
5 Male 51 Hydronephrosis and chronic pyelonephritis
6 Male 45 Chronic pyelonephritis
7 Female 54 Chronic pyelonephritis and hydronephrosis
8 Female 60 Renal cell carcinoma
9 Female 45 Chronic pyelonephritis and atrophy of the parenchyma
10 Female 38 Chronic pyelonephritis and hydronephrosis
11 Female 76 Renal cell carcinoma
12 Female 29 Hydronephrosis and atrophy of the parenchyma
13 Female 33 Hydronephrosis, xanthogranulomatosis and chronic pyelonephritis
14 Female 34 Chronic pyelonephritis and hydronephrosis
15 Male 67 Transitional cells carcinoma of the pelvis and ureter
16 Female 22 Ureteral duplication, with severe atrophy of the lower pole; hydronephrosis and hydroureter of the upper unit
17 Male 77 Renal cell carcinoma
Figure 1. Estimation of absolute renal uptake with technetium-99m dimercaptosuccinic 
acid (99mTc-DMSA) in a 28-year-old patient with a right kidney tumor diagnosed by 
computed tomography (a: in vivo image, posterior view; b: ex vivo image, posterior 
view; c: nephrectomy specimen, anterior view).
Right kidney estimated radioactivity: 25%
Estimated radioactivity: 29% Measured radioactivity: 30%
A
B C
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the kidneys that would be removed. All 
ROIs were visually checked for accuracy. In 
four cases, the ROI was not properly drawn 
by the isocontour method, and a new ROI 
was manually drawn. The number of counts 
per second in the kidneys was determined. 
Background corrections were performed us-
ing ROIs around the kidneys. All values were 
corrected for radioactive decay.
Estimation of kidney depth:
The depth of the kidneys in centimeters 
was estimated by the Tonnensen equations,10 
based on the weight (W) in kg and height (H) 
in cm of each patient, as follows:
Right kidney = 13.3 (W/H) + 0.7
Left kidney = 13.2 (W/H) + 0.7
Kidney attenuation correction 
and determination of the renal 
corrected counts per second:
Tissue attenuation corrections were per-
formed by taking into consideration the at-
tenuation of technetium-99m photons in water 
(0.15),11 which is the most similar analogy to hu-
man tissue. The following equation was used:
Renal counts 
per second
e –(0.15) x (kidney depth)
Renal corrected
counts per second
=
Determination of syringe counts 
per second:
The count per second was obtained 
from the syringe images, with correction for 
radioactive decay, and multiplication by the 
attenuation factor (2.8087). 
Estimation of the ARU of 
99mTc-DMSA using the images
The estimation of the ARU was based on 
the efficiency of the detector (counts/MBq x 
seconds), by dividing the syringe count per sec-
ond before injection by the radioactivity of the 
same syringe measured by the dose calibrator.
Syringe count per second 
before injection
Radioactivity of the 
syringe before injection
Efficiency of
the detector
=
The ARU was then calculated using the 
images of the kidneys before nephrectomy: 
ARU x 100
Renal corrected count 
per second/ efficiency 
of the detector
Radioactivity adminis-
tered to the patient
ARU using nephrectomy 
specimen images (ex vivo renal 
images) for evaluating the 
attenuation correction 
accuracy
Immediately after surgery, posterior view 
images of the nephrectomy specimens were 
obtained using the same scintillation camera as 
before, with the same acquisition parameters 
(Figure 1B). These images were not subjected 
to soft tissue attenuation (except for the at-
tenuation of the renal parenchyma itself ).
All ARU values were then recalcu-
lated using these images and the equation 
described above. These values were compared 
with the values obtained from the in vivo im-
ages and with the reference value. 
Determination of the 
reference value for the ARU 
of 99mTc-DMSA
Each nephrectomy specimen was placed 
in a plastic bag and fitted in the same dose 
calibrator chamber that had been used for 
radioactivity measurement on the syringes. 
After correcting all measurements for ra-
dioactive decay, the reference value for the 
ARU was determined for each excised kidney 
(Figure 1C) as a percentage of the injected 
dose, by dividing the nephrectomy specimen 
radioactivity by the injected dose radioactivity 
and multiplying by 100%, as follows:
Reference value of ARU = (specimen ra-
dioactivity/injected radioactivity) x 100%.
Statistical analysis
Linear regression analysis was used to 
compare the ARU calculated using in vivo and 
ex vivo images with the ARU from the refer-
ence method. It was also applied to compare 
the ARU values measured with the in vivo and 
ex vivo images in order to evaluate the simi-
larity of these values, which is related to the 
accuracy of the attenuation correction method 
applied to the in vivo images of kidneys.
Results
The labeling efficiency of the radiophar-
maceutical ranged from 98.7% to 99.3%. 
The mean ARU values obtained with the 
in vivo and ex vivo images and with the refer-
ence method were, respectively, 5.6%, 6.4% 
and 6.8%. The calculated ARU values for all 
patients are listed in Table 2.
The linear regression analysis comparing 
the ARU values obtained with the in vivo and 
ex vivo images and the reference method result-
ed in r-squared of 0.96 (in vivo image and the 
reference method, Figure 2) and 0.99 (ex vivo 
image and the reference method; Figure 3).
The attenuation correction method ap-
plied to the in vivo images was found to be 
efficient, since the values obtained with the 
in vivo and ex vivo images were very similar, 
with r-squared of 0.95.
discussion
Determination of the functional capa-
bility of an individual kidney is particularly 
Table 2. Absolute renal uptake (ARU) of technetium-99m dimercaptosuccinic acid 
(99mTc-DMSA): comparison with the reference value
Patient ARU, in vivo image (%) ARU, ex vivo image (%) Reference (nephrectomy specimen radioactivity) (%)
1 3.2 3.9 3.8
2 0.9 0.9 1.0
3 24.6 27.8 30.3
4 2.5 6.7 7.3
5 3.6 2.8 3.1
6 3.1 2.1 2.6
7 6.0 7.3 7.7
8 14.1 14.7 17.0
9 0.3 0.4 0.4
10 2.3 2.9 2.9
11 8.3 8.1 9.0
12 5.7 8.1 6.1
13 0.6 1.4 1.7
14 6.0 5.4 5.8
15 0.9 0.5 0.6
16 4.9 4.5 4.9
17 8.5 11.9 12.3
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Figure 2. Linear regression analysis between the reference method and the in vivo 
absolute renal uptake of technetium-99m dimercaptosuccinic acid (99mTc-DMSA).
Reference = 0.123781 + (1.19409 x in vivo uptake)
r- square = 0.96
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Figure 3. Linear regression analysis between the reference method and the ex vivo 
absolute renal uptake of technetium-99m dimercaptosuccinic acid (99mTc-DMSA).
Reference = -0.137464 + (1.08752 x ex vivo uptake)
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r- square = 0.99
important when nephrectomy is being con-
sidered. Many studies have evaluated different 
methods for quantifying 99mTc-DMSA up-
take.8,9,12 However, few studies have specifically 
addressed the use of the ARU measurement to 
evaluate the kidneys for nephrectomy purpos-
es.13,14 When surgery is considered, very precise 
measurement of the absolute renal function 
is important, since chronic renal failure after 
nephrectomy is a possibility.13 In addition, 
we have observed that nephrectomy provides 
a good opportunity to check the efficiency of 
the method used for absolute renal uptake 
estimation using 99mTc-DMSA.
Goldraich et al.15 also determined the 
absolute renal uptake in 142 children with vesi-
coureteral reflux based on the percentage of the 
injected dose of  99mTc-DMSA. Their technique 
was similar to that described by Raynaud16 
using 197Hg-chlormerodrin (197HgCl
2
), which 
was an innovative quantitative method at that 
time. Goldraich et al.15 reported a significant 
association between the degree of reflux 
nephropathy and the functional impairment 
measured by 99mTc-DMSA uptake. Their tech-
nique needed a correction factor consisting of 
standard radioactivity for renal depth, calcu-
lated according to a decreasing exponential 
curve that was obtained by plotting a series of 
measurements of the standard against increas-
ing thicknesses of a Plexiglas® cover.
Morris et al.17 measured the absolute renal 
uptake of  99mTc-DMSA in 160 children, based 
on injected counts, by subtracting the count in 
the syringe after injection from the count before 
injection. The attenuation correction used the 
geometric mean count between the anterior 
and posterior positions. They considered the 
thickness of the patient’s intervening tissue at 
the center of each kidney, measured with the 
patients in the prone and supine positions. 
They determined the count in the syringe 
before injection by acquiring an image for only 
five seconds, in order to avoid pixel overflow in 
the computer. In the present study, we preferred 
to use a lead cylinder attenuator.
Groshar et al. proposed the use of a 
quantitative SPECT method to estimate the 
absolute renal function,12 based on the tech-
nique of Iosilevsky et al.18 The latter is a very 
sophisticated method that avoids the need 
for renal depth determination. However, it 
is laborious and impractical, and depends on 
specific site standardizations, including the 
need to determine the threshold value for each 
institution. Groshar et al.12 did not use a gold 
standard test to confirm their final results. 
In the present method, we performed 
attenuation correction by using the renal 
depth estimated by the Tonnensen equa-
tions.10 which are simple for routine use and 
have been used by several authors.19,20 These 
equations may underestimate renal depth, as 
previously described by Taylor et al.21 Never-
theless, we were able to check the efficiency of 
this method by comparing the ARU measure-
ments of the in vivo and ex vivo images, which 
turned out to be very similar, with excellent 
correlation (r-squared = 0.95).
The use of the cylindrical device made of 
lead and PVC was essential for keeping the 
radioactivity dose within the linear range of 
the scintillation camera detector, with cor-
rection of the error due to dead time loss. A 
device of this nature can be easily developed 
in any institution.
In this study, we evaluated a simple meth-
od for determining the ARU before surgery 
using a reliable gold standard, which consisted 
of direct measurement of renal radioactivity in 
the nephrectomy specimen. The ARU values 
obtained were very similar to those of the ref-
erence method, with r-squared of 0.96. Using 
simple parameters, namely the radioactivity 
and count in the syringe and the count in the 
kidney, this method is easy to introduce into 
routine clinical practice. In particular, measure-
ment of the radioactivity and acquisition of 
an image of the syringe inside the lead device 
is necessary only once a day. Thus, the only 
parameters needed for each patient are the 
injected dose and the count in the kidney.
It is important to emphasize that the 
method proposed here was only performed on 
entopic kidneys that were being considered for 
nephrectomy, mostly with severely reduced 
function. Further studies are necessary in 
order to evaluate whether this method would 
be feasible for ectopic organs and kidneys with 
normal or mildly impaired function. 
The optimal time at which to determine 
the absolute renal uptake of  99mTc-DMSA has 
been reported to be six hours after injection. 
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By that time, it is postulated that the uptake 
will have reached a plateau.22 However, for 
ideal imaging characteristics, a time interval 
of 2-4 hours between injection and imaging is 
optimal, without any significant effect on ab-
solute 99mTc-DMSA uptake.23 The difference 
between the values obtained four hours and six 
hours after injection is less than 6%.24
The fact that the in vivo images were 
acquired three to four hours after administer-
ing the radiopharmaceutical, while the images 
of the nephrectomy specimens were acquired 
six to 24 hours later could represent a potential 
error in the in vivo ARU values, compared 
with the specimen ARU values. Neverthe-
less, we found a high correlation between 
the in vivo and specimen ARU values (r-
squared = 0.96), which suggests that there was 
no significant change in the renal uptake over 
this interval of time, at least for this group of 
patients, whose kidneys mainly presented low 
functional capability.
Thus, in the present study, a simplified 
method was used to quantify kidneys that were 
scheduled for nephrectomy. The in vivo ARU 
was compared with the gold standard, i.e. the 
“real” quantification of the functional capability 
of the resected kidney, which was determined 
as the percentage of the injected radioactivity 
present in the nephrectomy specimen.
CONCLUSIONS
The method described is simple and 
precise for estimating the ARU before ne-
phrectomy, without the need for imaging 
phantoms or complex equations. However, 
further studies are needed, in order to evaluate 
the usefulness of this method in kidneys with 
normal or mildly impaired function.
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RESUMO
Estimativa da captação renal absoluta com ácido dimercaptosuccínico marcado com tecnécio-
99m: comparação direta com a radioatividade medida em peças de nefrectomia
CONTEXTO E OBJETIVO: Os estudos com radionuclídeos são os mais adequados para se estimar a função 
renal. O ácido dimercaptosuccínico marcado com tecnécio-99m (DMSA-99mTc) é o radiofármaco de escolha 
para imagens de alta resolução dos rins, permitindo, também, estimar massa de parênquima renal funcio-
nante. O objetivo deste estudo foi avaliar um método mais simples para determinar-se a captação renal 
absoluta (CRA) de DMSA-99mTc antes de nefrectomias e validá-lo utilizando-se as contagens radioativas 
das próprias peças de nefrectomia como padrão-ouro.
TIPO DE ESTUDO E LOCAL: Estudo prospectivo, desenvolvido no Serviço de Medicina Nuclear do Depar-
tamento de Radiologia da Universidade Estadual de Campinas.
MÉTODOS: Foram estudados 17 pacientes (12 pacientes do sexo feminino, média de idade de 50,8 anos), 
selecionados para a realização de nefrectomia. A cintilografia renal foi realizada três a quatro horas após 
a administração venosa de 188,7 MBq de DMSA-99mTc, seis a 24 horas antes da cirurgia. A CRA in vivo 
foi determinada utilizando-se a radioatividade da seringa antes da injeção (medida com um calibrador 
de dose) e as imagens da seringa e dos rins, obtidas em uma câmara de cintilação. Após a cirurgia, o 
valor de referência para a CRA foi determinado medindo-se a radioatividade da peça de nefrectomia 
com o mesmo calibrador de dose. 
RESULTADOS: Os valores de CRA foram muito semelhantes àqueles obtidos com o método de referência, 
conforme foi demonstrado pela análise de regressão linear (r-quadrado = 0,96).
CONCLUSÃO: A estimativa da CRA com o método proposto antes de nefrectomiasparece ser acurado e 
aplicável ao uso rotineiro.
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